Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Plk1-mediated phosphorylation of Topors regulates p53 stability.

The Journal of biological chemistry - 10 Jul 2009

Yang Xiaoming, Li Hongchang, Zhou Zinan, Wang Wen-Horng, Deng Anping, Andrisani Ourania, Liu Xiaoqi

Abstract excerpt

Polo-like kinase 1 (Plk1) overexpression is associated with tumorigenesis by an unknown mechanism. Likewise, Plk1 was suggested to act as a negative regulator of tumor suppressor p53, but the mechanism remains to be determined. Herein, we have identified topoisomerase I-binding protein (Topors), a p53-binding protein, as a Plk1 target. We show that Plk1 phosphorylates Topors on Ser(718) in vivo. Significantly,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Cycle Proteins
Share to Genes, p53
Share to Neoplasm Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Polo-Like Kinase 1

Share to Protein Serine-Threonine Kinases

Share to Proto-Oncogene Proteins

Share to Tumor Suppressor Protein p53

Share to Ubiquitin-Protein Ligases

Source

Open in PubMed Open full text

Identifiers

PMID: 19473992
DOI: 10.1074/jbc.C109.001560
PMCID: PMC2707202

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Plk1-mediated phosphorylation of Topors regulates p53 stability.PMID 19473992Read ↗

Polo-like Kinase 1 as an emerging drug target: structure, function and therapeutic implicationsSemantic proximity Read ↗

Polo-like kinase inhibitors: an emerging opportunity for cancer therapeuticsSemantic proximity Read ↗

Polo-like kinase 2 targeting as novel strategy to sensitize mutant p53-expressing tumor cells to anticancer treatments.Semantic proximity Read ↗

Present and Future Perspective on PLK1 Inhibition in Cancer TreatmentSemantic proximity Read ↗

Regulation of topoisomerase II stability and activity by ubiquitination and SUMOylation: clinical implications for cancer chemotherapySemantic proximity Read ↗

The Emerging Role of Polo-Like Kinase 1 in Epithelial-Mesenchymal Transition and Tumor MetastasisSemantic proximity Read ↗

Polo-like kinase 1 (Plk1) overexpression enhances ionizing radiation-induced cancer formation in miceSemantic proximity Read ↗

The Mitotic Cancer Target Polo-Like Kinase 1: Oncogene or Tumor Suppressor?Semantic proximity Read ↗

Inhibition of Polo-like kinase 1 (PLK1) triggers cell apoptosis via ROS-caused mitochondrial dysfunction in colorectal carcinomaSemantic proximity Read ↗

Topors acts as a SUMO‐1 E3 ligase for p53 in vitro and in vivoSemantic proximity Read ↗

p53-Dependent and Cell Specific Epigenetic Regulation of the Polo-like kinases under Oxidative StressSemantic proximity Read ↗

The balance of Polo-like kinase 1 in tumorigenesisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.